Douglas Stewart
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (20)
It is estimated that 10% of individuals with a myeloid malignancy carry a germline susceptibility. Using the genome-first approach, in which individuals were ascertained on genotype alone, rather than clinical phenotype, we quantified the prevalence and penetrance of pathogenic germline variants in eight myeloid malignancy predisposition (gMMP) genes. ANKRD26 , CEBPA, DDX41, MECOM, SRP72, ETV6, RUNX1 and GATA2 , were analyzed from the Geisinger MyCode DiscovEHR ( n = 170,503) and the United Kingdom Biobank (UKBB, n = 469,595). We identified a high risk of myeloid malignancies (MM) (odds ratio[OR] all genes: DiscovEHR, 4.6 [95% confidential interval (CI) 2.1–9.7], p < 0.0001; UKBB, 6.0 [95% CI 4.3–8.2], p = 3.1 × 10 -27 ), and decreased overall survival (hazard ratio [HR] DiscovEHR, 1.8 [95% CI 1.3–2.6], p = 0.00049; UKBB, 1.4 [95% CI 1.2–1.8], p = 8.4 × 10 -5 ) amongst heterozygotes. Pathogenic DDX41 variants were the most commonly identified, and in UKBB showed a significantly increased risk of MM (OR 5.7 [95% CI 3.9–8.3], p = 6.0 × 10 -20 ) and increased all-cause mortality (HR 1.35 [95% CI 1.1–1.7], p = 0.0063). Through a genome-first approach, this study genetically ascertained individuals with a gMMP and determined their MM risk and survival.
Year:
2025
Background: Congenital anomalies are associated with an increased risk of childhood cancer. However, there is a knowledge gap about health outcomes for childhood cancer survivors with congenital anomalies. Methods: We included childhood cancer survivors from the Childhood Cancer Survivor Study (n = 22,247), comparing survivors with and without self-reported anomalies. Using Cox regression, we estimated HR and 95% confidence intervals (CI) of chronic health conditions (CHC) classified per the Common Terminology Criteria for Adverse Events from 1 (mild) to 5 (fatal) and subsequent malignant neoplasms (SMN), comparing survivors by anomaly status. We calculated age-, sex-, and calendar year–specific mortality rates and standardized mortality ratios for survivors compared with the US population. Results: Among survivors, 16.9% (n = 3,880) reported a congenital anomaly. Survivors with anomalies had a higher rate of any CHC (grades 1–5: HR, 1.24; 95% CI, 1.18–1.31), severe CHCs (grades 3–5: HR, 1.29; 95% CI, 1.19–1.40), and multiple CHCs of any grade (≥2 CHCs: HR, 1.31; 95% CI, 1.24–1.39; ≥3 CHCs: HR, 1.42; 95% CI, 1.33–1.52). Survivors with anomalies had an increased rate of soft-tissue sarcomas (HR, 1.96; 95% CI, 1.12–3.44). For deaths related to the original cancer diagnosis, survivors with anomalies (compared with those with no anomalies) had a lower mortality rate (0.64 vs. 0.90 per 1,000 person-years). Conclusions: We identified an increased rate of CHCs and SMNs among childhood cancer survivors with anomalies and lower mortality directly related to the cancer diagnosis. Impact: Future work will focus on the evaluation of genetic pathways that increase the risk of CHCs and SMNs.
Year:
2025
The Radiation Effects Research Foundation (RERF) conducts research on the health effects of atomic bomb (A-bomb) radiation, supported by the long-term cooperation of survivors and their children. In response to concerns from A-bomb survivors, their offspring, and the global community, RERF has investigated transgenerational radiation effects for many years. Currently, RERF is planning the Trio Genome Study (TGS), which will utilize advanced genome sequencing to examine potential genetic effects on the offspring of survivors. This study could yield significant findings but also presents ethical challenges, particularly in ensuring that results are returned responsibly to the community. RERF first held an international workshop to address ethical, legal, and social issues related to genomic analysis in 2020, followed by formation of stakeholder committees to align the study with community perspectives. Most recently, in December 2024, an international symposium further explored frameworks important to the TGS, including risk communication, benefit-sharing, community involvement, and return of secondary findings. In genomic analysis, secondary findings comprise a deliberate search for pathogenic variants in an established list of genes in disorders associated with life-threatening manifestations. Returning these secondary findings to research participants is crucial from the perspective of benefit-sharing. Discussions emphasized the need for transparency in the return of secondary findings, especially those with actionable health implications, including sharing the rationale behind providing information about genetic variants to research participants. These frameworks will guide not only future RERF studies but also genomic research worldwide, ensuring that the findings benefit participants and communities.
Year:
2025
Year:
2025
Background: Congenital anomalies are associated with an increased risk of childhood cancer. However, there is a knowledge gap about health outcomes for childhood cancer survivors with congenital anomalies. Methods: We included childhood cancer survivors from the Childhood Cancer Survivor Study ( n = 22,247), comparing survivors with and without self-reported anomalies. Using Cox regression, we estimated HR and 95% confidence intervals (CI) of chronic health conditions (CHC) classified per the Common Terminology Criteria for Adverse Events from 1 (mild) to 5 (fatal) and subsequent malignant neoplasms (SMN), comparing survivors by anomaly status. We calculated age-, sex-, and calendar year–specific mortality rates and standardized mortality ratios for survivors compared with the US population. Results: Among survivors, 16.9% ( n = 3,880) reported a congenital anomaly. Survivors with anomalies had a higher rate of any CHC (grades 1–5: HR, 1.24; 95% CI, 1.18–1.31), severe CHCs (grades 3–5: HR, 1.29; 95% CI, 1.19–1.40), and multiple CHCs of any grade (≥2 CHCs: HR, 1.31; 95% CI, 1.24–1.39; ≥3 CHCs: HR, 1.42; 95% CI, 1.33–1.52). Survivors with anomalies had an increased rate of soft-tissue sarcomas (HR, 1.96; 95% CI, 1.12–3.44). For deaths related to the original cancer diagnosis, survivors with anomalies (compared with those with no anomalies) had a lower mortality rate (0.64 vs. 0.90 per 1,000 person-years). Conclusions: We identified an increased rate of CHCs and SMNs among childhood cancer survivors with anomalies and lower mortality directly related to the cancer diagnosis. Impact: Future work will focus on the evaluation of genetic pathways that increase the risk of CHCs and SMNs.
Year:
2025
Purpose: DROSHA , DGCR8 , and DICER1 regulate miRNA biogenesis and are commonly mutated in cancer. Although DGCR8 and DICER1 germline pathogenic variants (GPV) cause autosomal dominant tumor predisposition, no association between DROSHA GPVs and clinical phenotypes has been reported. Experimental Design: After obtaining informed consent, sequencing was performed on germline and tumor samples from all patients. The occurrence of germline DROSHA GPVs was investigated in large pediatric and adult cancer datasets. The population prevalence of DROSHA GPVs was investigated in the UK Biobank and Geisinger DiscovEHR cohorts. Results: We describe nine children from eight families with heterozygous DROSHA GPVs and a diagnosis of pineoblastoma ( n = 8) or Wilms tumor ( n = 1). A somatic second hit in DROSHA was detected in all eight tumors analyzed. All pineoblastoma tumors analyzed were classified as miRNA processing–altered 1 subtype. We estimate the population prevalence of germline DROSHA loss-of-function variants to be 1:3,875 to 1:4,843 but find no evidence for increased adult cancer risk. Conclusions: This is the first report of DROSHA- related tumor predisposition. As pineoblastoma and Wilms tumor are also associated with DICER1 GPVs, our results suggest that the tissues of origin for these tumors are uniquely tolerant of general miRNA loss. The miRNA processing–altered 1 pineoblastoma subtype is associated with older age of diagnosis and better outcomes than other subtypes, suggesting DROSHA GPV status may have important clinical and prognostic significance. We suggest that genetic testing for DROSHA GPVs be considered for patients with pineoblastoma, Wilms tumor, or other DICER1 -/ DGCR8 -related conditions and propose surveillance recommendations through research studies for individuals with DROSHA GPVs.
Year:
2025
Neurofibromatosis type 1 (NF1) is an autosomal dominant condition in which patients are heterozygous for a disruptive pathogenic variant in the NF1 gene. The most characteristic feature of the condition NF1 is the neurofibroma, a benign, multi-cellular tumor which initiates when a cell of the Schwann cell lineage gains a somatic pathogenic variant of the other NF1 allele. Neurofibromas developing at nerve termini in the skin are termed “cutaneous” neurofibromas (cNFs), while those developing within larger nerves are termed “plexiform.” Most patients develop cNFs beginning in late childhood or early adulthood, continuing throughout life at variable rates. Some patients may develop only a few cNFs, while others suffer from thousands. There are no reliably effective physical or pharmaceutical therapies besides surgical removal. Although these are not life-threatening, they are disfiguring and can interfere with normal life functions. To provide a resource for research, we developed short-term cNF Schwann cell cultures from NF1 patients, from which we subsequently established the first semi-immortalized cNF cell lines through transduction with wild-type human telomerase reverse transcriptase ( hTERT ) and murine cyclin-dependent kinase 4 ( mCdk4 ) genes. Here we present molecular, cellular, and functional characterization of these cell lines, which will be of utility for investigating and developing NF1 cNF therapies.
Year:
2025
With the increasing use of comprehensive germline genetic testing of children and adolescents with cancer, it has become evident that pathogenic variants (PV) in adult-onset cancer predisposition genes (aoCPG) underlying adult-onset cancer predisposition syndromes, such as Lynch syndrome or hereditary breast and ovarian cancer, are enriched and reported in 1% to 2% of children and adolescents with cancer. However, the causal relationship between PVs in aoCPGs and childhood cancer is still under investigation. The best-studied examples include heterozygous PVs in mismatch repair genes associated with Lynch syndrome in children with mismatch repair deficient high-grade glioma, heterozygous PVs in BARD1 in childhood neuroblastoma, and heterozygous PVs in BRCA2 in children with rhabdomyosarcoma. The low penetrance for pediatric cancers is considered to result from a combination of the low baseline risk of cancer in childhood and the report of only a modest relative risk of disease in childhood. Therefore, we do not advise that healthy children empirically be tested for PVs in an aoCPG before adulthood outside a research study. However, germline panel testing is increasingly being performed in children and adolescents with cancer, and exome and genome sequencing may be offered more commonly in this population in the future. The precise pediatric cancer risks and spectra associated with PVs in aoCPGs, underlying cellular mechanisms and somatic mutational signatures, as well as treatment response, second neoplasm risks, and psycho-oncological aspects require further research.
Year:
2024
Genetic predisposition to neuroblastoma (NB) is relatively rare. Only 1% to 2% of patients have a family history of NB, 3% to 4% of cases present with bilateral or multifocal primary tumors, and occasional patients have syndromes that are associated with increased NB risk. Previously, a germline pathogenic variant (GPV) in PHOX2B was associated with Hirschsprung disease and congenital central hypoventilation syndrome. Recently, certain GPVs were shown to be responsible for congenital central hypoventilation syndrome and NB predisposition. Also, several groups determined that activating GPVs in ALK accounted for a substantial number of familial NB. Finally, there are additional genes and cancer predisposition syndromes in which NB occurs with greater frequency or that have been associated with NB based on genome-wide association studies. We review the evidence for all these genes and whether there is sufficient evidence to warrant surveillance. We review recommended surveillance for hereditary patients with NB, including minor updates to surveillance recommendations that were published previously in 2017.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2022
Collaborators (49)
Amanda Janitz
Assistant Professor in Epidemiology
-
Sharon E. Plon
Professor and Assistant Dean
Baylor College of Medicine
Smita Bhatia
Professor
The University of Alabama
Eric J. Chow
Seattle Children's Hospital
Sharon Diskin
Associate Professor
University of Pennsylvania
Lisa J. McReynolds
National Institutes of Health
Dominik T. Schneider
Witten/Herdecke University
Garrett Brodeur
Professor
Children's Hospital of Philadelphia
Sang Lee
Johns Hopkins University School of Medicine
Dominique Stoppa-Lyonnet
Institut Curie
Joseph Neglia
Professor
University of Minnesota Medical School Twin Cities
Megan Frone
National Institutes of Health
Kuan-lin Huang
Icahn School of Medicine at Mount Sinai
Kenji Kamiya
Hiroshima University
William Foulkes
Full Professor
McGill University
Jeremy M. Schraw
Voluntary Assistant Professor
Baylor College of Medicine
Frank Lin
Baylor College of Medicine Department of Pediatrics
Louis P. Dehner
-
Eduard Serra
Researcher
Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol
Gregory Armstrong
Endowed Chair in Epidemiology and Cancer Control
St. Jude Children's Research Hospital
Andrew Bauer
Associate Professor
University of Pennsylvania
Kara Maxwell
Assistant Professor
University of Pennsylvania
David Wilson
Professor
Washington University in Saint Louis School of Medicine
Nathalie Japkowicz
American University
Philip Lupo
Professor
Emory University
Yutaka Yasui
Fred Hutchinson Cancer Research Center
Jaishri Blakeley
Johns Hopkins University
Kenneth S. Chen
University of Texas Southwestern Medical Center
Jo Lynne Rokita
Director, Brain Tumor Institute Bioinformatics Core
Children's National Health System
David Watson
Assistant Professor of Biostatistics
Mayo Clinic
Margaret Wallace
Professor
University of Florida College of Medicine
Lindsay Frazier
Professor and Institute Physician
Dana-Farber Cancer Institute
Arikuni Uchimura
Laboratory Chief
-
Angela C. Hirbe
Washington University School of Medicine
Giselle L. Saulnier Sholler
-
Meritxell Carrio
Associate researcher
Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol
Michael Sargen
Lasker Clinical Research Scholar
National Cancer Institute
Sarah Scollon
Assistant Professsor/Genetic Counselor
Baylor College of Medicine
Piyushkumar Mundra
Children's Cancer Institute Australia
Deeann Wallis
The University of Alabama
Donald Parsons
Professor
Baylor College of Medicine
Philip Rosenberg
Principal Investigator
National Cancer Institute
Sogol Mostoufi-Moab
Associate Professor of Pediatrics
Children's Hospital of Philadelphia
Lucie M. Turcotte
University of Minnesota
Joshua Schiffman
Professor
University of Utah Health
Martin Zenker
Full professor, head of department
University Hospital Magdeburg
Allison Pribnow
Clinical Assistant Professor
Stanford University
Zois Boukouvalas
Assistant Professor
American University
Anita Ng
Feinstein Institute for Medical Research
Make your next move.
Prepare your application
Review drafts before you send them.